COP Chemotherapy Protocol
The **COP protocol** (Cyclophosphamide, Vincristine, Prednisolone) is a combination cytotoxic therapy commonly used in veterinary oncology, primarily for the treatment of lymphoma. > **Clinical Warning:** Vincristine is a severe vesicant. Extravasation causes severe tissue necrosis. **Clinical Pearl:** While most oncologists prefer a CHOP-type protocol, high-dose COP is a highly useful and relatively straightforward protocol for use in a non-specialist setting.
Mechanism: The COP protocol utilizes three distinct mechanisms to target neoplastic cells: * **Cyclophosphamide**: An alkylating agent that cross-links DNA strands โ prevents DNA replication and transcription โ induces cell death. * **Vincristine**: Binds to **tubulin** โ inhibits microtubule formation and mitotic spindle assembly โ arrests cell division in metaphase. * **Prednisolone**: A glucocorticoid that binds to specific intracellular receptors โ alters gene expression โ induces apoptosis in neoplastic lymphocytes.
Dosing by species
- COP Protocol - Induction (Cyclophosphamide) ยท 250 mg/m2 ยท PO ยท q21d ยท First 6 months ยท Administer with Furosemide to prevent haemorrhagic cystitis.
- COP Protocol - Induction (Vincristine) ยท 0.70 mg/m2 ยท IV ยท q7d for 4 weeks, then q21d ยท First 6 months ยท On q21d schedule, give on the same day as cyclophosphamide.
- COP Protocol - Induction (Prednisolone) ยท 2 mg/kg (week 1), 1.5 mg/kg (week 2), 1 mg/kg (week 3), 1 mg/kg thereafter ยท PO ยท q24h (weeks 1-3), then q48h ยท First 6 months ยท Tapering dose schedule.
- COP Protocol - Adjunct (Furosemide) ยท 1 mg/kg ยท PO ยท q12h ยท For 48h (4 doses) concurrent with cyclophosphamide ยท Administered to promote diuresis and reduce risk of haemorrhagic cystitis.
- COP Protocol - Maintenance after 6 months (Cyclophosphamide) ยท 250 mg/m2 ยท PO ยท q28d ยท Months 6 to 12 ยท Stop protocol after 12 months and monitor for relapse.
- COP Protocol - Maintenance after 6 months (Vincristine) ยท 0.70 mg/m2 ยท IV ยท q28d ยท Months 6 to 12 ยท Administer with cyclophosphamide.
- COP Protocol - Maintenance after 6 months (Prednisolone) ยท 1 mg/kg ยท PO ยท q48h ยท Months 6 to 12 ยท Stop protocol after 12 months and monitor for relapse.
- Alternative to Cyclophosphamide (Chlorambucil) ยท 20 mg/m2 ยท PO ยท As directed replacing cyclophosphamide ยท Ongoing ยท Use if haemorrhagic cystitis develops or if blood is noted on urine dipstick and culture is negative.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Routes of administration
Contraindications
- Severe neutropenia (< 2 x 10^9/L)
- Pre-existing haemorrhagic cystitis
- Known MDR1 mutation (requires extreme caution/dose adjustment for vincristine)
Adverse effects
- Myelosuppression (neutropenia)
- Haemorrhagic cystitis (cyclophosphamide)
- Gastrointestinal toxicity (vomiting, diarrhoea, anorexia)
- Tissue necrosis if extravasated (vincristine)
Drug interactions
- Cimetidine ยท Inhibits hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics. ยท major
Monitoring
- Haematology (prior to each vincristine treatment)
- Biochemistry (prior to first treatment, then minimum every 6 months)
- Free-catch urine dipstick (prior to each cyclophosphamide administration to check for blood)
- Urine culture (if blood is noted on dipstick)
Overdose
**Severe toxicity:** Overdose of these chemotherapeutics can lead to fatal myelosuppression, severe gastrointestinal sloughing, sepsis, and death. Extravasation of vincristine causes severe, progressive tissue necrosis requiring immediate management (e.g., hyaluronidase, warm compresses).
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโs current label.